Wells Fargo & Company Aim Immuno Tech Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 400 shares of AIM stock, worth $92. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 1,147
65.13%
Holding current value
$92
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
9.01MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$995,9000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$457,4010.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$160,6010.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$106,7230.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$105,2860.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $11.1M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...